New study provides unique perspective from the viewpoint of HCPs and patients/caregivers regarding their effectiveness

Possibly the first survey in the EU to evaluate the effectiveness of additional risk minimisation measures (aRMMs) for Bipolar I Disorder, this study treads new ground. It does so, firstly, by adopting a unique viewpoint – that of HCPs, patients and caregivers. And secondly by implementing a web-based survey tool to assess the effectiveness of aRMMs in relation to aripiprazole treatment across 12 EU countries.

From partial response rates, findings point to limited effectiveness: aRMMs proved useful to some, but the ability of risk minimisation tools to reach or educate the target audience was limited. What the study highlights clearly, however, is the need for an innovative framework and better regulatory guidance around survey-based studies to reduce operational challenges and encourage participation.  

Click here to read the research paper

Share

Receive Our Newsletter

Please fill out the form below to receive our newsletter. Alternatively email